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ABSTRACT 
Objective: To study the antihyperlipidemic and anti atherosclerotic activity of Cassia fistula extracts in experimentally induced atherosclerotic rats.  
Methods: In this study, the antihyperlipidemic activity of Cassia fistula bark was evaluated by the administration of high fat diet. Atherosclerosis 
was induced in wistar rats by feeding with high cholesterol diet for 21 d. Oral feeding of cholesterol (500 mg/kg b.w./day) dissolved in coconut oil 
(0.5 ml/rat/day) caused an elevation in total cholesterol, LDL cholesterol, VLDL cholesterol triglycerides serum of rats.  
Results: Administration of Cassia fistula extracts (methanolic and ethyl acetate extract at 500 mg/kg respectively) along with high cholesterol diet 
reduced the raised serum level of total cholesterol, triglyceride, LDL, VLDL and increased the serum HDL level as compared to the control group 
(High cholesterol group). Histopathology study of heart has shown decrease in myocardial degeneration and inflammation which may be attributed 
to the anti atherosclerotic activity of the Cassis fistula bark extracts.  
Conclusion: These results suggested that Cassia fistula bark possess significant antihyperlipidemic activity. 
Keywords: Antihyperlipidemic, Antiatherosclerotic, Cassia fistula, Caesalpiniaceae. 
 
INTRODUCTION  
Hyperlipidemia is a condition of abnormally elevated levels of any or 
all lipids or lipoproteins in the blood i.e. the fatty substances are 
found in the blood. This condition is also called 
hypercholesterolemia or hyperlipoproteinemia. Atherosclerosis is a 
disease of blood vessels and known colloquially as “hardening of the 
arteries” [1]. It is characterized by the accumulation of fatty 
substance, cholesterol, cellular waste products, calcium and other 
substances in the inner lining of an artery. The World Health 
Organization (WHO) predicted that heart diseases and stroke are 
becoming more deadly, with a projected combined death of 24 
million by 2030 [2]. Due to accumulation of fat, cholesterol and 
other substances, plaque builds up inside the arteries. Over time, 
plaque hardens and narrows the arteries.  
With the emerging worldwide interest in adopting and studying 
traditional systems and exploiting their potential based on different 
health care systems, the evaluation of the rich heritage of traditional 
medicine is essential. In this regard, we have decided to explore the 
Cassia fistula. Cassia fistula L. (Cassia) family Caesalpiniaceae 
commonly known as Amulthus and in English popularly called 
“Indian Laburnum” has been extensively used in Ayurvedic system 
of medicine for various ailments [3]. It is having various traditional 
uses as a tonic, astringent, febrifuge and strong purgative. The leaves 
are laxative and used externally as emollient, a poultice is used for 
chilblains in insect bites, swelling, rheumatism and facial paralysis. 
The fruit pulp is used for constipation, colic, chlorosis and urinary 
disorders. The bark possesses tonic and antidysentric properties, it is 
also used for skin complaints, leprosy, jaundice, syphilis and heart 
diseases. It is one of the ingredients of the marketed preparation 
Constivac (Lupin Herbal) for a bowel regulation and constipation, and 
Pilex, Purian (Himalaya Drug Company) for piles and detoxification.  
The fruit and stem bark extract shows various activities like 
antipyretic, anti-inflammatory, antioxidant, antidiabetic, 
hypolipidemic, hepatoprotective, antimicrobial, antitumor, antiulcer 
etc. However, there are no reports on the Antihyperlipidemic 
activity of Cassia fistula bark. The present study was designed to 
investigate the Anti-hyperlipidemic activity of methanolic extract of 
Cassia fistula bark in Wistar rats in an attempt to establish 
traditional use of this plant. 
MATERIALS AND METHODS  
Plant material 
The whole plant of Cassia fistula was collected from Seshachalam hills, 
Tirupati, Chitoor district, Andhra Pradesh in the month of January and 
was identified and authenticated by Dr. K. Madhava chetty. The 
powdered plant material was successively extracted in 500 ml of ethyl 
acetate and methanol using simple distillation [4]. The extracts were 
finally stored in air tight containers for further use.  
Drugs and chemicals 
Atorvastatin was obtained from Axis clinicals Ltd, Hyderabad. All 
other reagents and chemicals were of analytical grade. 
Animals 
Adult wistar albino rats (170–200 g) were used for the 
pharmacological activities. They were kept in polypropylene cages 
at 25±2 ° C, with relative humidity 45-55% under 12h light and dark 
cycles. All the animals were acclimatized to the laboratory 
conditions for a week before use. They were fed with standard 
animal feed and water ad libitum. The Institutional Animal Ethical 
Committee of Gokaraju Rangaraju College of Pharmacy, Hyderabad, 
with Reg. No. CPCSEA/CH/ORG/2001/1910/3, approved the study. 
Acute toxicity studies 
The acute toxicity of the methanol extract and ethyl acetate extract 
of bark was determined using Swiss albino mice of either sex, which 
were maintained under standard conditions. The animals were 
fasted overnight prior to the experiment. Fixed dose (OECD 
Guideline No. 423) method of CPCSEA was adopted for the toxicity 
studies. Mortality was observed at the dose of 5000 mg/kg for the 
extracts. Hence 1/10th of the LD50 dose i.e. 500 mg/kg of the ethanol 
extracts was selected for the study [5]. 
In vitro HMG CoA reductase inhibitor activity 
3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) is a 
transmembrane glycoprotein, located on the endoplasmic reticulum. 
This enzyme catalyzes the four-electron reduction of HMG-CoA to 
coenzyme A (CoA) and mevalonate, which is the rate-limiting step in 
sterol biosynthesis [6]. The activity of HMGR is controlled through 
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synthesis, degradation, and phosphorylation in order to maintain 
the concentration of mevalonate derived products. In addition to the 
physiological regulation of HMGR, the human enzyme has been 
targeted successfully by drugs in the clinical treatment of high 
serum cholesterol levels. Controlling serum cholesterol levels has an 
important therapeutic role as hypercholesterolemia often leads to 
the development of atherosclerosis and consequently to 
cardiovascular pathologies, which might result in myocardial 
infarction and stroke. Recent evidence suggests that a disturbance of 
cholesterol homeostasis contributes to the development of a chronic 
inflammatory state [7]. 
Antihyperlipidemic activity 
Antihyperlipidemic activity: Animals were divided into 5 groups 
with 6 animals per group.  
Group 1: Normal control.  
Group 2: Hyperlipidemic control (Vehicle 1 ml/100g/day p. o)  
Group 3: Hyperlipidemic treated with Atorvastatin (10 mg/kg/day p. o)  
Group 4: Hyperlipidemic treated with MECF bark (500 mg/kg/day p. o)  
Group 5: Hyperlipidemic treated with EECF bark (500 mg/kg/day p. o)  
The animals were administered with corresponding treatments for 
one month. 
Induction of Hyperlipidemia 
High cholesterol diet was prepared by mixing cholesterol 2%, 
sodium cholate 1% and coconut oil 2%, with powdered standard 
animal food. The diet which was prepared as pellets was placed in 
the cage carefully and was administered for 20 d [8, 9]. 
Biochemical assays for lipids 
The serum triglycerides and HDL (High Density Lipoproteins) and 
total cholesterol were measured using span diagnostic kit [5]. 
Cholesterol, triglycerides and HDL profile were estimated using 
standard monograph. (Low Density Lipoproteins) LDL cholesterol 
was calculated using formula LDL = Total Cholesterol-HDL-
Triglycerides/5 VLDL was calculated using the formula (Very Low 
Density Lipoproteins) VLDL = Triglycerides/5. The aorta was fixed 
by 10% formalin for histopathological studies. 
Measurement of coronary disease risk factor 
Atherogenic Index (AI), which is a measure of the atherogenic 
potential of an agent, was calculated using the following formula and 
the results were tabulated.  
Atherogenic Index (AI) = LDL-cholesterol/HDL-cholesterol 
% Protection = AI of control-AI of treated group ×100 AI of control 
Determination of antioxidant parameters 
For estimation of antioxidant parameters, the livers were homogenized 
(10%w/v) in ice cold phosphate buffer and centrifuged at 2000 rpm for 
5 min at 4 ˚C in a cooling centrifuge. After centrifugation, the supernatant 
was separated and stored for further analysis.  
Assay for Thiobarbituric acid reactive substance (Maleic 
dialdehyde) 
Lipid peroxidation was estimated colorimetrically in the liver by 
quantifying TBARS according to the method of Ohkawa and Ohishi et 
al. [10]. For the estimation, 0.5 ml of supernatant was treated with 
0.2 ml of 8.1% sodium dodecyl sulphate, 1.5 ml of 20% acetic acid 
adjusted to pH 3.5 with NaOH and 1.5 ml of 0.8% solution of 
thiobarbituric acid. The volume of the mixture was adjusted to 4.0 
ml with distilled water and heated in a water bath at 85˚C for 60 
min. Light pink color was developed. After cooling with tap water, 
1.0 ml of distilled water and 5.0 ml of mixture of n-butanol and 
pyridine (15:1, V/V) was added. The mixture was shaken vigorously 
and then centrifuged at 4000 rpm for 5 min. After centrifugation, the 
organic layer was separated and its absorbance was read at 532 nm 
using a UV-visible spectrophotometer against a reagent blank. The 
amount of TBARS was calculated by using 1.56×105M-1 cm-1 as 
molar extinction co-efficient and the level of lipid peroxidation was 
expressed as nmol of maleic dialdehyde/mg of protein (MDA). 
Assay for reduced glutathione content 
Reduced glutathione (GSH) was determined colorimetrically by the 
method of Ellman et al. [11]. The Ellman’s reagent was prepared by 
dissolving 39.6 mg DTNB in 10 ml phosphate buffer (pH=7). For 
estimation of GSH, 0.5 ml of supernatant was treated with 3.0 ml of 
ethanol and 0.5 ml of Ellman’s reagent. The absorbance of the 
developed yellow color was read at 412 nm using a UV-visible 
spectrophotometer against a reagent blank. The reduced glutathione 
content was calculated by using 13,600M-1 cm-1 as the molar 
extinction co-efficient as nmol GSH formed/mg protein. 
Determination of superoxide dismutase activity 
Superoxide dismutase activity was assayed in terms of its ability to 
inhibit the radical-mediated autoxidation of epinephrine; using the 
method described by Misra and Fridovich et al. [12]. The reaction 
mixture consisted of 0.5 ml of carbonate buffer (pH=9.7), 0.5 ml of 
supernatant, 0.1 ml of EDTA solution (1×10-4 M) and 0.1 ml of 
epinephrine solution (3×10-3 M). The changes in the absorbance of this 
solution were read at 480 nm for 3 min at 30 sec intervals using a UV-
visible spectrophotometer (against reagent blank). The activity of 
superoxide dismutase was calculated by using 4020 M-1 cm-1 as molar 
extinction co-efficient and expressed as Units/min/mg of protein. 
Histopathological study of heart 
For histopathology, the rats were sacrificed by cervical decapitation 
and their aortas were dissected out. During the procedure, ice was 
used to keep the aorta samples fresh and avoid any degradation. The 
aortas were stored in 10% formalin solution and sent to a local 
pathological laboratory for hematoxyline and eosin staining. 
Statistical analysis 
The results are expressed as mean±standard error of mean (SEM). 
The data were analyzed using one-way analysis of variance (one-
way ANOVA) followed by Turkey’s test for comparison between 
groups. The criterion for statistical significance was p<0.05. 
 
Table 1: In vitro inhibition of HMG CoA Reductase activity on 
Cassia fistula bark extracts 
Concentration % inhibition IC50 µg/ml 
Blank 0  
MECF (100 µg/ml) 43±0.12 150 µg/ml 
MECF (500 µg/ml) 85±1.01 
EECF (100 µg/ml) 20±0.02 250 µg/ml 
EECF (500 µg/ml) 32±0.02 
Standard (Atorvastatin 100 µg/ml) 65±1.10 75 µg/ml 
Values are expressed as mean±SEM, (n=6). 
  
Table 2: Effects of methanolic and ethyl acetate extract of Cassia fistula on TC, TG, LDL, VLDL and HDL on rats fed on HFD. 










Control 104.2±2.47 79.83±1.68 37.73±2.30 15.8±0.33 46.83±2.15 
Cholesterol control 219.66±11.08a 185.5±6.94 162.96±11.05 30.3±1.16 26.33±0.61 
MECF (500 mg/kg) 114.16±3.68ns,** 115.5±5.5a,**,ns 49.76±3.80a,**,a 23±1.10a,**,ns 41.66±0.88ns,**,b 
EECF (500 mg/kg) 183.16±5.38a,**,a 141±2.7a,*,A 110.46±5.81a,ns 27.6±0.91a,*,a 47±1.43ns,**,a 
Standard (Atorvastatin) 110.33±3.43 104.1±5.3 46.5±4.02 20.83±1.07 42.5±1.17 
Values are expressed as mean±SEM, (n=6). All the groups were compared with control group, cholesterol control group and standard group. 
Significant values are expressed as c 
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Table 3: Effects of methanolic and ethyl acetate extracts of Cassia fistula on the biochemical parameters of the rats fed on a high-fat diet 
Groups HMG CoA/Mevalonate ratio Superoxide dismutase Glutathione levels Maleic dialdehyde levels 
Control 0.32±0.06 13.11±0.15 10.11±0.13 3.638±0.25 
Cholesterol control 0.54±0.06 8.48±0.17 7.30±0.12 8.99±0.18 
MECF (500 mg/kg) 1.14±0.04a,**,a 11.46±0.19a,*,a 10.06±0.01a,*,a 6.65±0.15a,*,b 
EECF (500 mg/kg) 1.63±0.05a,**,a 9.79±0.18a,*,a 7.54±0.12a,*,a 5.28±0.14a,ns,b 
Standard (Atorvastatin) 2.21±0.09 12.71±0.17 10.17±0.13 3.84±0.34 
Values are expressed as mean±SEM, (n=6). All the groups were compared with control group, cholesterol control group and standard group. 
Significant values are expressed as control group (a=p<0.01, b=p<0.05), cholesterol control (**= p<0.01, *= p<0.05) and standard (a= p<0.01, b= 
p<0.05), ns-non significant. 
 
Table 4: Effect of Cassia fistula extracts on atherogenic index and % Protection 
Groups Atherogenic Index % Protection 
Control 1.7±0.06 - 
Cholesterol control 5.9±0.3 - 
MECF (500 mg/kg) 2.76±0.11ns,**,ns 52.82±4.1 
EECF (500 mg/kg) 3.01±0.09a,**,A 65.50±3.9 
Standard (Atorvastatin) 2.45±0.16 40.47±3.8 
Values are expressed as mean±SEM, (n=6). All the groups were compared with control group, cholesterol control group and standard group. 
Significant values are expressed as control group (a=p<0.01, b=p<0.05), cholesterol control (**= p<0.01, *= p<0.05) and standard (A = p<0.01, B = 




Fig. 1: Cholesterol control rat Fig. 2: Effect of MECF treated rat 
  
Fig. 3: Effect of EECF treated rat Fig. 4: Standard treated 
Fig. 1-4: Histopathological changes such as myocardial degeneration and inflammation of aorta occurred in rats during high fat diet 
intoxication and prevention by the treatment with methanolic (500 mg/kg) and ethyl acetate extract (500 mg/kg) of bark of Cassia fistula 
when compared to the standard Atorvastatin (10 mg/kg). The slides were studied under 200x magnification 
 
RESULTS 
Administration of Cassia fistula extracts in the doses of 2000 mg/kg 
and 5000 mg/kg resulted in no mortalities or evidence of adverse 
effects implying that Cassia fistula is non toxic. This showed that 
Cassia fistula was safe up to a dose of 5000 mg/kg. Phytochemical 
screening of the plant extract showed different phytoconstituents 
viz. carbohydrates, steroids, saponins and flavonoids, tannins and 
phenolic compounds. Presence of glycosides, triterpenoids, 
saponins, alkaloids and flavonoids are known to have 
antihyperlipidemic properties. Observed lipid lowering activity 
could be attributed to the presence of flavonoids in the extract. 
In vitro HMG CoA Reductase inhibitor activity 
Extracts of Cassia fistula bark was evaluated for HMG CoA Reductase 
inhibitor activity and was found that methanolic extract of Cassia 
fistula bark inhibited HMG-CoA reductase by 43% inhibition at 100 
µg/ml, and 85% inhibition at 500 µg/ml. Ethyl acetate extract of 
Cassia fistula bark inhibited HMG-CoA reductase by 20% inhibition 
at 100µg/ml and 32% inhibition at 500 µg/ml (table 1). This shows 
that methanolic extract was found to be more potent when 
compared to that of ethyl acetate extract.  
The antiatherosclerotic activity of methanolic and ethyl acetate 
extract of Cassia fistula was evaluated in rats receiving high 
cholesterol diet. Determination of body weight in experimentally 
induced atherosclerosis is considered to be a positive factor to find 
out the prognosis of disease [13].  
Results indicated increase in body weight of animals from the beginning 
to the end of the experiment in all five groups, but at the end there is 
decrease in body weight in extracts treated groups as compared to high 
cholesterol diet treated group. High atherogenic index (A. I.) is believed 
to be an important factor for atherosclerosis. Results indicated that 
extracts were capable of potentially decreasing this risk factor (table 4). 
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In the present study, HMG CoA reductase activity was indirectly 
measured in terms of the ratio between HMG CoA and mevalonate 
[14]. The ratio was found to be inversely proportional to HMG CoA 
reductase activity, indicated that an increase in the ratio inferred a 
decrease in the enzyme activity. The methanolic extract of Cassia 
fistula produced a significant increase in HMG CoA/mevalonate ratio 
in liver as compared to the normal group (table 3). 
Effect on serum lipid profile 
Hyperlipidemia was induced by giving high cholesterol diet to the 
rats and we have found that total cholesterol, triglyceride, LDL, 
VLDL levels have been increased and decrease of HDL levels. After 
treatment with methanolic extract and ethyl acetate extract of Cassia 
fistula at a dose of 500 mg/kg reduced the serum cholesterol levels 
significantly (p<0.01) and standard group atorvastatin at a dose of 
10 mg/kg showed significant (p<0.01) reduction in total cholesterol 
levels, triglyceride, LDL, VLDL, AI, increased HDL more % protection 
of the heart when compared to that of hyperlipidemic rats (table 2). 
Effect on body weights 
Post treatment with methanolic extract and ethyl acetate extract of 
Cassia fistula at a dose of 500 mg/kg decreased the serum body 
weights significantly (p<0.01) and standard group atorvastatin at a 
dose of 10 mg/kg showed significant increase in total HDL levels 
when compared to that of hyperlipidemia rats.  
Effect on antioxidant parameters 
It was found that in rats treated with methanolic and ethyl acetate 
extract of Cassia fistula at a dose of 500 mg/kg has increased the 
Superoxide dismutase levels, GSH levels significantly (p<0.01) and 
standard group atorvastatin at a dose of 10 mg/kg showed 
significant (p<0.01) increase in Superoxide dismutase levels when 
compared to that of hyperlipidemic rats. It was found that in rats 
treated with methanolic and ethyl acetate extract of Cassia fistula at 
a dose of 500 mg/kg has decreased the maleic dialdehyde levels 
(p<0.01) and standard group atorvastatin at a dose of 10 mg/kg 
showed significant (p<0.01) decrease in maleic dialdehyde levels 
when compared to that of hyperlipidemic rats (table 3). 
DISCUSSION 
There was distinct raise in the level of serum total cholesterol, 
triglycerides, phospholipids, LDL, VLDL and reduction in the level of 
good cholesterol carrier HDL in the animals treated with 
atherogenic diet. Elevated level of blood cholesterol especially LDL 
was the major risk factor for the coronary heart disease and HDL as 
cardio protective protein.  
HMG CoA reductase is the rate limiting enzyme in the cholesterol 
biosynthetic pathway. It converts HMG CoA to mevalonate, so HMG 
CoA reductase inhibition would prevent the formation of 
mevalonate which in turn would decrease the sterol biosynthesis. In 
vitro HMG CoA reductase inhibition study has shown that the 
methanolic and ethyl acetate extract could inhibit the HMG CoA 
reductase. This elucidates the mechanism of action by which the 
Cassia fistula possesses antihyperlipidemic activity.  
Atherosclerosis leads to tissue oxidant stress, due to reduction in 
antioxidant capacity generated by high cholesterol diet. Clinical 
studies suggest hyperlipidemia as one of the major risk factors for 
coronary disease, while preclinical observations demonstrate that 
atherosclerosis promotes accumulation of oxidized low-density 
lipoprotein (Ox-LDL) in the arterial wall, which plays a major role in 
the initiation and progression of the cardiovascular dysfunction 
associated with atherosclerosis [15].  
Since oxidation of LDL plays a significant role in atherogenesis, 
amelioration of oxidative stress is equally important as controlling or 
decreasing hyperlipidemia. When summarized with the above results, 
the imbalance between oxidative stress generation and antioxidants 
formation could occur after feeding a high cholesterol diet.  Nevertheless, 
extracts could prevent this pathological process, which indicated its 
therapeutic and preventive effect on hepatosteatosis induced by high 
cholesterol diet. Histopathology examination of aorta has shown normal 
integrity of cell membrane was maintained. Myocardial degeneration 
and inflammation was decreased in the groups treated with methanolic 
and ethyl acetate extracts of Cassia fistula when compared to that of 
cholesterol control group (fig. 1, fig. 2, fig. 3 and fig. 4). 
CONCLUSION 
Extracts were capable of potentially decreasing atherogenic Index 
and have increased the percentage protection. Superoxide 
dismutase and glutathione peroxidase levels have increased in the 
groups treated with extracts. Histopathology studies showed that 
the damage i.e. myocardial degeneration and inflammation that is 
caused due to atherosclerosis was found to be recovered. Hence it 
can be concluded that methanolic and ethyl acetate extract of Cassia 
fistula has antihyperlipidemic and anti-atherosclerotic activity on 
rats fed on a high cholesterol diet. 
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